Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Susana N. Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J. Monk, Andrew Clamp, Emily Prendergast, Ana Oaknin, Kari Ring, Nicoletta Colombo, Robert W. Holloway, Manuel Rodrigues, Hye Sook Chon, Charlie Gourley, Alessandro D. Santin, Premal H. Thaker, Christine Gennigens, Gregg Newman, Erin Salinas, Hagop Youssoufian, Kathleen N. Moore, Stephanie Lustgarten, David M. O'Malley, Toon Van Gorp, Rachel N. Grisham

Open source

DOI: 10.1200/jco-25-00112
Published: 2025-09
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-00112,
  title = {Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201},
  author = {Susana N. Banerjee and Els Van Nieuwenhuysen and Carol Aghajanian and Véronique D'Hondt and Bradley J. Monk and Andrew Clamp and Emily Prendergast and Ana Oaknin and Kari Ring and Nicoletta Colombo and Robert W. Holloway and Manuel Rodrigues and Hye Sook Chon and Charlie Gourley and Alessandro D. Santin and Premal H. Thaker and Christine Gennigens and Gregg Newman and Erin Salinas and Hagop Youssoufian and Kathleen N. Moore and Stephanie Lustgarten and David M. O'Malley and Toon Van Gorp and Rachel N. Grisham},
  year = {2025},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-25-00112},
  url = {https://doi.org/10.1200/jco-25-00112}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
AU  - Susana N. Banerjee
AU  - Els Van Nieuwenhuysen
AU  - Carol Aghajanian
AU  - Véronique D'Hondt
AU  - Bradley J. Monk
AU  - Andrew Clamp
AU  - Emily Prendergast
AU  - Ana Oaknin
AU  - Kari Ring
AU  - Nicoletta Colombo
AU  - Robert W. Holloway
AU  - Manuel Rodrigues
AU  - Hye Sook Chon
AU  - Charlie Gourley
AU  - Alessandro D. Santin
AU  - Premal H. Thaker
AU  - Christine Gennigens
AU  - Gregg Newman
AU  - Erin Salinas
AU  - Hagop Youssoufian
AU  - Kathleen N. Moore
AU  - Stephanie Lustgarten
AU  - David M. O'Malley
AU  - Toon Van Gorp
AU  - Rachel N. Grisham
PY  - 2025
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-25-00112
UR  - https://doi.org/10.1200/jco-25-00112
ER  -

APA

Banerjee, S. N., Nieuwenhuysen, E. V., Aghajanian, C., D'Hondt, V., Monk, B. J., Clamp, A., Prendergast, E., Oaknin, A., Ring, K., Colombo, N., Holloway, R. W., Rodrigues, M., Chon, H. S., Gourley, C., Santin, A. D., Thaker, P. H., Gennigens, C., Newman, G., Salinas, E., Youssoufian, H., Moore, K. N., Lustgarten, S., O'Malley, D. M., Gorp, T. V., & Grisham, R. N. (2025). Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00112

Source records

crossref · retrieved 2026-09-25T12:13:33.846Z